CRSP stock touches 52-week low at $35.52 amid market challenges

Crispr Therapeutics AG (NASDAQ: NASDAQ:CRSP) stock has reached a 52-week low, dipping to $35.52, as the biotechnology sector faces headwinds and investor sentiment wanes. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 22.07 and holds more cash than debt on its balance sheet, suggesting financial stability despite market pressures. The company, known for its pioneering work in gene editing, has seen its shares significantly retreat from previous levels, marking a stark contrast to the industry’s earlier optimism. Over the past year, Crispr Therapeutics AG’s stock has undergone a precipitous decline, with a 1-year change showing a substantial decrease of 45.75%. This downturn reflects broader market trends and possibly investor concerns over the company’s pipeline progress and the commercial viability of its gene-editing technology. InvestingPro analysis reveals 12 additional key insights about CRSP’s financial health and market position, available in the comprehensive Pro Research Report.

In other recent news, CRISPR Therapeutics has seen several key developments. The company announced that Chief Operating Officer Julianne Bruno will step down in April 2025 after six years, during which she contributed significantly to the company’s hematology and oncology programs. On the financial front, Citi analysts have adjusted their price target for CRISPR Therapeutics to $82, maintaining a Buy rating, and highlighting the company’s expanding treatment centers for its Casgevy therapy. Evercore ISI upgraded CRISPR Therapeutics from In Line to Outperform, raising the price target to $99, driven by optimism about upcoming catalysts and the company’s cash reserves of $1.9 billion. Conversely, Stifel analysts have taken a more cautious approach, reducing their price target to $49 while maintaining a Hold rating, citing concerns about the market uptake of Casgevy. Despite these varied analyst opinions, CRISPR Therapeutics continues to advance its pipeline, with anticipated updates on several programs, including CTX112 for B-cell malignancies and systemic lupus erythematosus. The company also reported growth in Casgevy cell collections, signaling ongoing progress in its gene-editing initiatives. These recent developments reflect the dynamic landscape of CRISPR Therapeutics’ operations and strategic direction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.